These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22392523)

  • 1. Estimating utilities for chronic kidney disease, using SF-36 and SF-12-based measures: challenges in a population of veterans with diabetes.
    Rajan M; Lai KC; Tseng CL; Qian S; Selim A; Kazis L; Pogach L; Sinha A
    Qual Life Res; 2013 Feb; 22(1):53-64. PubMed ID: 22392523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.
    Ahmad H; Campbell JA; van der Mei I; Taylor BV; Xia Q; Zhao T; Palmer AJ
    Qual Life Res; 2023 Dec; 32(12):3373-3387. PubMed ID: 37522942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
    Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
    Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life of young adults and adolescents with chronic kidney disease.
    Tong A; Wong G; McTaggart S; Henning P; Mackie F; Carroll RP; Howard K; Craig JC
    J Pediatr; 2013 Oct; 163(4):1179-85.e5. PubMed ID: 23800404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
    Harrison MJ; Lunt M; Verstappen SM; Watson KD; Bansback NJ; Symmons DP
    Health Qual Life Outcomes; 2010 Feb; 8():21. PubMed ID: 20149253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
    Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
    Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping utility scores from a disease-specific quality-of-life measure in bariatric surgery patients.
    Sauerland S; Weiner S; Dolezalova K; Angrisani L; Noguera CM; García-Caballero M; Rupprecht F; Immenroth M
    Value Health; 2009; 12(2):364-70. PubMed ID: 20667063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
    McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
    J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis.
    Wong MG; Ninomiya T; Liyanage T; Sukkar L; Hirakawa Y; Wang Y; Wyld MLR; Morton RL; Chadban S; Howard K; Jardine MJ
    Nephrology (Carlton); 2019 Jun; 24(6):605-614. PubMed ID: 30039893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Condition Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by Preference-Based Health Index.
    Hanmer J; Cherepanov D; Palta M; Kaplan RM; Feeny D; Fryback DG
    Med Decis Making; 2016 Feb; 36(2):264-74. PubMed ID: 26314728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
    Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
    Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the Performance of 2 Health Utility Measures in the Medicare Health Outcome Survey (HOS).
    Jia H; Lubetkin EI; DeMichele K; Stark DS; Zack MM; Thompson WW
    Med Decis Making; 2018 Nov; 38(8):983-993. PubMed ID: 30403580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
    Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
    Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and estimates of utility in chronic kidney disease.
    Gorodetskaya I; Zenios S; McCulloch CE; Bostrom A; Hsu CY; Bindman AB; Go AS; Chertow GM
    Kidney Int; 2005 Dec; 68(6):2801-8. PubMed ID: 16316356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.
    Wyld M; Morton RL; Hayen A; Howard K; Webster AC
    PLoS Med; 2012; 9(9):e1001307. PubMed ID: 22984353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putting the 'Q' in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures.
    Mann R; Gilbody S; Richards D
    Soc Psychiatry Psychiatr Epidemiol; 2009 Jul; 44(7):569-78. PubMed ID: 19011721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial.
    Raisch DW; Feeney P; Goff DC; Narayan KM; O'Connor PJ; Zhang P; Hire DG; Sullivan MD
    Cardiovasc Diabetol; 2012 Jul; 11():35. PubMed ID: 22515638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 preference-based SF-6D in chronic kidney disease.
    Davison SN; Jhangri GS; Feeny DH
    Value Health; 2009; 12(2):340-5. PubMed ID: 18657096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.